News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
316,314 Results
Type
Article (15701)
Company Profile (286)
Press Release (300316)
Multimedia
Podcasts (65)
Webinars (12)
Section
Business (91683)
Career Advice (162)
Deals (16210)
Drug Delivery (38)
Drug Development (53779)
Employer Resources (31)
FDA (6914)
Job Trends (5560)
News (165352)
Policy (12342)
Tag
Academia (964)
Accelerated approval (8)
Adcomms (14)
Allergies (72)
Alliances (26198)
ALS (93)
Alzheimer's disease (999)
Antibody-drug conjugate (ADC) (145)
Approvals (6997)
Artificial intelligence (182)
Autoimmune disease (33)
Automation (7)
Bankruptcy (111)
Best Places to Work (4795)
BIOSECURE Act (6)
Biosimilars (75)
Biotechnology (234)
Bladder cancer (82)
Brain cancer (31)
Breast cancer (247)
Cancer (2251)
Cardiovascular disease (170)
Career advice (144)
Career pathing (2)
CAR-T (162)
CDC (4)
Cell therapy (432)
Cervical cancer (11)
Clinical research (44997)
Collaboration (832)
Company closure (2)
Compensation (434)
Complete response letters (27)
COVID-19 (1158)
CRISPR (70)
C-suite (326)
Cystic fibrosis (92)
Data (2659)
Denatured (13)
Depression (64)
Diabetes (202)
Diagnostics (1775)
Digital health (4)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (121)
Drug pricing (36)
Drug shortages (3)
Duchenne muscular dystrophy (163)
Earnings (35401)
Editorial (21)
Employer branding (4)
Employer resources (29)
Events (53988)
Executive appointments (589)
FDA (8209)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (722)
Gene editing (137)
Generative AI (12)
Gene therapy (373)
GLP-1 (469)
Government (1239)
Grass and pollen (3)
Guidances (160)
Healthcare (7147)
HIV (12)
Huntington's disease (30)
IgA nephropathy (47)
Immunology and inflammation (136)
Immuno-oncology (8)
Indications (31)
Infectious disease (1240)
Inflammatory bowel disease (139)
Inflation Reduction Act (9)
Influenza (33)
Intellectual property (120)
Interviews (18)
IPO (8163)
IRA (12)
Job creations (1044)
Job search strategy (135)
Kidney cancer (8)
Labor market (15)
Layoffs (235)
Leadership (5)
Legal (2146)
Liver cancer (46)
Longevity (8)
Lung cancer (334)
Lymphoma (165)
Machine learning (13)
Management (7)
Manufacturing (261)
MASH (92)
Medical device (3562)
Medtech (3568)
Mergers & acquisitions (8572)
Metabolic disorders (556)
Multiple sclerosis (81)
NASH (13)
Neurodegenerative disease (118)
Neuropsychiatric disorders (35)
Neuroscience (1640)
NextGen: Class of 2025 (2142)
Non-profit (897)
Now hiring (26)
Obesity (257)
Opinion (110)
Ovarian cancer (92)
Pain (71)
Pancreatic cancer (103)
Parkinson's disease (166)
Partnered (10)
Patents (226)
Patient recruitment (184)
Peanut (40)
People (28700)
Pharmaceutical (46)
Pharmacy benefit managers (6)
Phase I (15545)
Phase II (20737)
Phase III (13524)
Pipeline (1640)
Policy (76)
Postmarket research (992)
Preclinical (6554)
Press Release (32)
Prostate cancer (101)
Psychedelics (44)
Radiopharmaceuticals (229)
Rare diseases (418)
Real estate (1882)
Recruiting (12)
Regulatory (10680)
Reports (22)
Research institute (991)
Resumes & cover letters (17)
Rett syndrome (10)
RNA editing (15)
RSV (12)
Schizophrenia (95)
Series A (131)
Series B (98)
Service/supplier (1)
Sickle cell disease (57)
Special edition (15)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (2197)
State (1)
Stomach cancer (6)
Supply chain (29)
Tariffs (16)
The Weekly (51)
Vaccines (303)
Venture capital (45)
Weight loss (136)
Women's health (18)
Worklife (2)
Date
Today (65)
Last 7 days (259)
Last 30 days (1390)
Last 365 days (19509)
2025 (13588)
2024 (21853)
2023 (23966)
2022 (30247)
2021 (31137)
2020 (26590)
2019 (18341)
2018 (13441)
2017 (15635)
2016 (13739)
2015 (16812)
2014 (12452)
2013 (9312)
2012 (9526)
2011 (9706)
2010 (9313)
Location
Africa (201)
Alabama (57)
Alaska (2)
Arizona (65)
Arkansas (5)
Asia (30711)
Australia (4465)
California (5538)
Canada (1603)
China (635)
Colorado (197)
Connecticut (207)
Delaware (160)
Europe (45710)
Florida (692)
Georgia (174)
Hawaii (2)
Idaho (16)
Illinois (320)
India (24)
Indiana (126)
Iowa (7)
Japan (214)
Kansas (75)
Kentucky (6)
Louisiana (4)
Maine (13)
Maryland (647)
Massachusetts (4460)
Michigan (92)
Minnesota (225)
Mississippi (3)
Missouri (28)
Montana (14)
Nebraska (4)
Nevada (28)
New Hampshire (15)
New Jersey (1414)
New Mexico (12)
New York (1456)
North Carolina (713)
North Dakota (6)
Northern California (2537)
Ohio (144)
Oklahoma (9)
Oregon (22)
Pennsylvania (1021)
Puerto Rico (7)
Rhode Island (24)
South America (275)
South Carolina (6)
Southern California (2161)
Tennessee (31)
Texas (689)
United States (18826)
Utah (87)
Virginia (114)
Washington D.C. (37)
Washington State (456)
West Virginia (1)
Wisconsin (31)
316,314 Results for "enlivex therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
September 10, 2025
·
5 min read
Press Releases
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
June 11, 2025
·
4 min read
Press Releases
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
July 29, 2025
·
5 min read
Press Releases
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
August 15, 2025
·
4 min read
Press Releases
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
April 23, 2025
·
4 min read
Press Releases
Enlivex Selected to Present at Israeli BioMed 2025 Conference
May 20, 2025
·
3 min read
Press Releases
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
August 19, 2025
·
6 min read
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Enlivex Therapeutics Ltd. is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m. ET.
June 20, 2024
·
4 min read
Deals
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares.
May 28, 2024
·
6 min read
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares and clinical milestone-linked warrants.
May 29, 2024
·
5 min read
1 of 31,632
Next
